Results 281 to 290 of about 4,466,693 (321)

A Single-Center Analysis of Patient Characteristics and Overall Survival in Patients with Resectable Gallbladder Cancer. [PDF]

Healthcare (Basel)
Öztürk NB, Dadamyan A, Jamil LH.
europepmc   +1 more source

PTBP3 Mediates IL-18 Exon Skipping to Promote Immune Escape in Gallbladder Cancer. [PDF]

Adv Sci (Weinh)
Zhao C, Zhao JW, Zhang YH, Zhu YD, Yang ZY, Liu SL, Tang QY, Yang Y, Wang HK, Shu YJ, Dong P, Wu XS, Gong W.   +12 more
europepmc   +1 more source

Super-Enhancer Reprograming Driven by SOX9 and TCF7L2 Represents Transcription-Targeted Therapeutic Vulnerability for Treating Gallbladder Cancer. [PDF]

Adv Sci (Weinh)
Yan S, Liu Z, Wang T, Sui Y, Wu X, Shen J, Pu P, Yang Y, Wu S, Qiu S, Wang Z, Jiang X, Feng F, Li G, Liu F, Zhao C, Liu K, Feng J, Li M, Man K, Wang C, Tang Y, Liu Y.   +22 more
europepmc   +1 more source

Correction: Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer. [PDF]

Cancer Immunol Immunother
Tan Y, Liu K, Zhu C, Wang S, Wang Y, Xue J, Ning C, Zhang N, Chao J, Zhang L, Long J, Yang X, Zeng D, Zhao L, Zhao H.   +14 more
europepmc   +1 more source

Erratum: DGCR5 Promotes Gallbladder Cancer by Sponging MiR-3619-5p via MEK/ERK1/2 and JNK/p38 MAPK Pathways: Erratum. [PDF]

J Cancer
Liu S, Chu B, Cai C, Wu X, Yao W, Wu Z, Yang Z, Li F, Liu Y, Dong P, Gong W.   +10 more
europepmc   +1 more source

Complete response of gallbladder cancer treated with gemcitabine and cisplatin chemotherapy combined with durvalumab: A case report and review of literature.

World J Gastrointest Oncol
Chen K, Feng X, Shi Y, Li XL, Shi ZR, Lan X.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Gallbladder cancer

Nature Reviews Disease Primers, 2022
Gallbladder cancer (GBC) is the most common cancer of the biliary tract, characterized by a very poor prognosis when diagnosed at advanced stages owing to its aggressive behaviour and limited therapeutic options. Early detection at a curable stage remains challenging because patients rarely exhibit symptoms; indeed, most GBCs are discovered ...
Juan C. Roa, Patricia García, Vinay K. Kapoor, Shishir K. Maithel, Milind Javle, Jill Koshiol   +5 more
semanticscholar   +6 more sources

Gallbladder Cancer

Surgical Clinics of North America
Gallbladder carcinoma (GBC) is the most common biliary epithelial malignancy, with an estimated incidence of 1.13 cases per 100,000 in the United States (Hundal and Shaffer in Clin Epidemiol 6:99-109, 2014 1; Henley et al. in Cancer Epidemiol Biomarkers Prev 24:1319-1326, 2015 2).
Clayton T, Marcinak, Daniel E, Abbott
semanticscholar   +5 more sources

Gallbladder cancer

Current Treatment Options in Gastroenterology, 2006
Gallbladder cancer (GBC) is the most common malignancy of the biliary tract and the fifth most common gastrointestinal (GI) cancer. In addition to global inter-country variations in incidence, large racial and ethnic variations have been noted within countries. High incidence rates of GBC have been described in North India, for example.
Sanjeev Misra, Arun Chaturvedi, Naresh C Misra   +2 more
openaire   +5 more sources